HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NTRA

Natera, Inc. (NASDAQ)

Healthcare — Diagnostics & Research

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Strong Buy 1.5 / 5 21 analysts
$276.27
+$4.82 (+1.78%)
Target: $264.57 (-4.2%)
Sign in to add NTRA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$39.57B
P/E Ratio (TTM)-
Forward P/E-1343.01
EPS (TTM)$-1.63
Dividend Yield-
Profit Margin-9.05%
Revenue Growth38.80%
ROE-15.02%
Debt/Equity13.53
Recommendation Strong Buy 1.5
Analyst Target$264.57
Analysts21
Indexes NASDAQ

Technical Indicators

RSI (14)86.9
Beta1.54
SMA 20-
SMA 40-
52-Week High$279.42
52-Week Low$131.81
50-Day Avg$216.56
200-Day Avg$210.12
Avg Volume$1.57M
Volume$1.85M

Performance Analysis

NEUTRAL

NTRA presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($279.42), which may indicate limited upside.
- RSI at 86.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 38.8% year-over-year.
- Operating at a loss with -9.0% margin.
+ Wall Street consensus is "Strong Buy" from 21 analysts.
- Average analyst target of $264.57 implies 4.2% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report